{"schema_version":"secwatch.filing_event.v1","accession":"0001725160-22-000199","form_type":"8-K","ticker":"ZNTL","cik":"0001725160","company_name":"Zentalis Pharmaceuticals, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.895173+00:00","generated_at":"2026-06-22T01:37:19.123247+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Zentalis Q3 cash $421.7M, ZN-c3 dose optimization extends USC trial; Cyclin E biomarker strategy set","bullets":["Cash $421.7M as of Sep 30, 2022; runway into Q1 2025.","R&D expenses $42.2M (down 22% YoY); G&A $12.0M (up 35% YoY).","ZN-c3 dose optimization extends USC trial timeline; update expected H1 2023.","Cyclin E amplification/overexpression selected as biomarker for ZN-c3 monotherapy in ovarian cancer.","Appointed new CMO (Carrie Brownstein), CSO (Kevin Bunker), CTO (Mark Lackner); added board member Jan Skvarka."],"urls":{"canonical":"https://secwatch.observer/filing/0001725160-22-000199","json":"https://secwatch.observer/filing/0001725160-22-000199.json","markdown":"https://secwatch.observer/filing/0001725160-22-000199.md","text":"https://secwatch.observer/filing/0001725160-22-000199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1725160/000172516022000199/0001725160-22-000199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1725160/000172516022000199/zntl-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:37:19.123247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a59e6b1eb23e82e7fdf44e4441dfba7ee460f993","claim":"Zentalis Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516022000199/0001725160-22-000199-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}